Artelo Biosciences, Inc. has started a public offering of its common stock and/or pre-funded warrants, managed by R.F. Lafferty & Co., Inc. The offering is subject to market conditions and SEC regulations, with details available on the SEC website or from R.F. Lafferty & Co., Inc. Artelo Biosciences focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions. The company also has a digital asset treasury strategy to maximize stakeholder value. Forward-looking statements in the press release outline the potential risks and uncertainties associated with the offering. For more information, visit www.artelobio.com.

Read more at GlobeNewswire: Artelo Biosciences Announces Proposed Underwritten Public